Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 501–600 of 1,005
Franchi, F., Rollini, F., Aggarwal, N. R., Hu, J., Kureti, M., Durairaj, A., Duarte, V. E., Cho, J. R., Been, L. F., Zenni, M. M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023402 · Cited by 101
Research progress of quercetin in cardiovascular disease
Zhang, W. W., Yan, Z., Fang, Y., Dong, M., & Ren, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1203713 · Cited by 130
“Antiplatelet therapy encompasses a range of medications, such as aspirin, P2Y12 inhibitors and glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, which have demonstrated their effectiveness in reducing MI and thrombotic complications risk (146).”
BackgroundWhy does ticagrelor induce dyspnea?
Faioni, E. M., & Cattaneo, M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0547 · Cited by 98
Aungraheeta, R., Conibear, A. E., Butler, M., Kelly, E., Nylander, S., Mumford, A. D., & Mundell, S. J. (2016) · Blood · doi:10.1182/blood-2016-03-707844 · Cited by 96
Moll, F. L., Baumgärtner, I., Jaff, M. R., Nwachuku, C., Tangelder, M. J. D., Ansel, G. M., Adams, G. L., Zeller, T., Rundback, J. H., GROSSO, M. A., et al. (2018) · Journal of Endovascular Therapy · doi:10.1177/1526602818760488 · Cited by 105
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 117
“By contrast, ticagrelor is indicated for ACS whether treated medically or by PCI, since efficacy was seen in both settings.(20) As regards standard DAPT, current guidelines(29,30) endorse treatment for 6–12 months, followed by aspirin monotherapy.”
MethodSehested, T. S. G., Carlson, N., Hansen, P. W., Gerds, T. A., Charlot, M. G., Torp-Pedersen, C. T., Køber, L., Gislason, G., Hlatky, M. A., & Fosbøl, E. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz104 · Cited by 108
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators, Schulz, S., Angiolillo, D. J., Antoniucci, D., Bernlochner, I., Hamm, C. W., Jaitner, J., Laugwitz, K., Mayer, K., von Merzljak, B., et al. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9527-3 · Cited by 102
Effect of P2Y12 inhibitors on inflammation and immunity
Storey, R. F., & Thomas, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1068 · Cited by 97
Self-citationGareau, A. J., Brien, C. D., Gebremeskel, S., Liwski, R., Johnston, B., & Bezuhly, M. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9874-1 · Cited by 106
Chen, H., Tran, D., Yang, H., Nylander, S., Birnbaum, Y., & Ye, Y. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06978-y · Cited by 105
Central sleep apnea: pathophysiologic classification
Javaheri, S., & Badr, M. S. (2022) · SLEEP · doi:10.1093/sleep/zsac113 · Cited by 109
Thrane, P. G., Olesen, K. K. W., Thim, T., Gyldenkerne, C., Mortensen, M. B., Kristensen, S. D., & Mæng, M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.025 · Cited by 110
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study
Siller-Matula, J. M., Delle‐Karth, G., Lang, I. M., Neunteufl, T., Koziński, M., Kubica, J., Maurer, G., Linkowska, K., Grzybowski, T., Huber, K., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04639.x · Cited by 101
Kaiser, C. A., Galatius, S., Jeger, R. V., Gilgen, N., Jensen, J. S., Naber, C. K., Alber, H. F., Wanitschek, M. M., Eberli, F. R., Kurz, D. J., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.013520 · Cited by 100
Structural and functional characterization of a specific antidote for ticagrelor
Buchanan, A. G., Newton, P., Pehrsson, S., Inghardt, T., Antonsson, T., Svensson, P., Sjögren, T., Öster, L., Janefeldt, A., Sandinge, A.-S., et al. (2015) · Blood · doi:10.1182/blood-2015-01-622928 · Cited by 96
Klein, M. D., Williams, A. K., Lee, C. R., & Stouffer, G. A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311963 · Cited by 96
Heart Failure Around the World
Tromp, J., Ferreira, J. P., Janwanishstaporn, S., Shah, M., Greenberg, B., Zannad, F. M., & Lam, C. S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1585 · Cited by 99
Schiele, F., Aktaa, S., Rossello, X., Ahrens, I., Claeys, M. J., Collet, J.-P., Fox, K. A. A., Gale, C. P., Huber, K., Iakobishvili, Z., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaa037 · Cited by 93
Kosuge, M., Ebina, T., Hibi, K., Morita, S., Endo, M., Maejima, N., Iwahashi, N., Okada, K., Ishikawa, T., Umemura, S., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.10.005 · Cited by 99
Koskinas, K. C., Räber, L., Zanchin, T., Wenaweser, P., Stortecky, S., Moschovitis, A., Khattab, A. A., Pilgrim, T., Blöchlinger, S., Moro, C., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002053 · Cited by 93
Angiolillo, D. J., Curzen, N. P., Gurbel, P. A., Vaitkus, P. T., Lipkin, F., Li, W., Jakubowski, J. A., Zettler, M. E., Effron, M. B., & Trenk, D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.032 · Cited by 94
Medical Management After Coronary Stent Implantation: A Review
Brilakis, E. S., PATEL, V. G., & Banerjee, S. (2013) · JAMA · doi:10.1001/jama.2013.7086 · Cited by 93
Iqbal, J., Sumaya, W., Tatman, V., Parviz, Y., Morton, A. C., Grech, E. D., Campbell, S., Storey, R. F., & Gunn, J. P. (2013) · EuroIntervention · doi:10.4244/eijv9i1a10 · Cited by 92
Self-citationCharacterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI
Giustino, G., Mehran, R., Dangas, G., Kirtane, A. J., Redfors, B., Généreux, P., Brener, S. J., Prats, J., Pocock, S., Deliargyris, E., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.018 · Cited by 100
“Of note, the benefits of ticagrelor in this trial did not begin to emerge until several weeks after initiation, and they continued to diverge throughout the 1-year follow-up period, as predicted from the present study (26).”
Darmon, A., Bhatt, D. L., Elbez, Y., Aboyans, V., Anand, S. S., Bosch, J., Branch, K. R., Connolly, S. J., Dyal, L., Eikelboom, J. W., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx658 · Cited by 98
Self-citationSchunkert, H., Boening, A., von Scheidt, M., Lanig, C., Gusmini, F., de Waha, A., Kuna, C., Fach, A., Grothusen, C., Oberhoffer, M. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz185 · Cited by 98
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Luca, L. D., Steg, P. G., Bhatt, D. L., Capodanno, D., & Angiolillo, D. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022125 · Cited by 94
Self-citationWelsh, R. C., Rao, S. V., Zeymer, U., Thompson, V. P., Huber, K., Kochman, J., McClure, M. W., Gretler, D. D., Bhatt, D. L., Gibson, C. M., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.964197 · Cited by 91
Self-citationVarenhorst, C., Alström, U., Scirica, B. M., Hogue, C. W. J., Åsenblad, N., Storey, R. F., Steg, P. G., Horrow, J. C., Mahaffey, K. W., Becker, R. C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.021 · Cited by 91
Self-citationTicagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Gersh, B. J. (2010) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79737-0 · Cited by 91
Raposeiras‐Roubín, S., Faxén, J., Íñiguez, A., Henriques, J. P. S., D’Ascenzo, F., Saucedo, J., Szummer, K. E., Jernberg, T., James, S. K., González‐Juanatey, J. R., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.103 · Cited by 98
Self-citationThe Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT), Ozaki, Y., Katagiri, Y., Onuma, Y., Amano, T., Muramatsu, T., Kozuma, K., Otsuji, S., Ueno, T., Shiode, N., et al. (2018) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-018-0516-y · Cited by 90
“1 3 results of the landmark Platelet Inhibition and Patient Outcomes (PLATO) trial [39].”
BackgroundTang, Y., Wang, W., Yang, M. H., Zhang, K., Chen, J., Qiao, S., Yan, H., Wu, Y., Huang, X., Xu, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030190 · Cited by 92
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 119
Rao, S. V., Dai, D. W. H., Subherwal, S., Weintraub, W. S., Brindis, R., Messenger, J. C., Lópes, R. D., & Peterson, E. D. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.05.010 · Cited by 93
Percutaneous coronary intervention in the elderly
Wang, T. Y., Gutiérrez, A., & Peterson, E. D. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.184 · Cited by 101
Harold, J. G., Bass, T. A., Bashore, T. M., Brindis, R. G., Brush, J. E., Burke, J. A., DEHMER, G. J., Deychak, Y. A., Jneid, H. M., Jollis, J. G., et al. (2013) · Circulation · doi:10.1161/cir.0b013e318299cd8a · Cited by 102
Jeong, Y., Kim, I., Park, Y., Kang, M.-K., Koh, J., Hwang, S., Kwak, C. H., & Hwang, J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.05.007 · Cited by 90
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 94
Self-citationBackhaus, T., Fach, A., Schmucker, J., Fiehn, E., Garstka, D., Stehmeier, J., Hambrecht, R., & Wienbergen, H. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1192-0 · Cited by 92
Cai, A., Yan, W., Wang, C., & Liu, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202111993 · Cited by 90
Ducrocq, G., Amarenco, P., Labreuche, J., Alberts, M. J., Mas, J., Ohman, E. M., Goto, S., Lavallée, P. C., Bhatt, D. L., & Steg, P. G. (2012) · Circulation · doi:10.1161/circulationaha.112.141572 · Cited by 90
Self-citationAradi, D., Tornyos, A., Pintér, T., Vorobcsuk, A., Kónyi, A., Faluközy, J., Veress, G., Magyari, B., Horváth, I., & Komócsi, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.023 · Cited by 99
Gaudino, M. F. L., Angiolillo, D. J., Franco, A. D., Capodanno, D., Bakaeen, F. G., Farkouh, M. E., Fremes, S. E., Holmes, D. R., Girardi, L. N., Nakamura, S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013032 · Cited by 99
D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 100
Self-citationGuideline For Stable Coronary Artery Disease
César, L. A. M., Ferreira, J., Armaganijan, D., Gowdak, L. H. W., Mansur, A. D. P., Bodanese, L., Sposito, A. C., Sousa, A. C., Aj, C., Markman, B., et al. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2014s004 · Cited by 124
Amin, A. P., Bachuwar, A., Reid, K. J., Chhatriwalla, A. K., Salisbury, A. C., Yeh, R. W., Kosiborod, M., Wang, T. Y., Alexander, K. P., GOSCH, K. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.044 · Cited by 89
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Gargiulo, G., Windecker, S., Vranckx, P., Gibson, C. M., Mehran, R., & Valgimigli, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023952 · Cited by 97
Berwanger, O. B., Nicolau, J. C., Carvalho, A. C., Jiang, L., Goodman, S. G., Nicholls, S. J., Parkhomenko, A. N., Валерьевич, А. О., Tajer, C. D., Málaga, G., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0612 · Cited by 89
Stone, S. G., Serrao, G. W., Mehran, R., Tomey, M. I., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Möckel, M., et al. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001360 · Cited by 93
Perioperative Management of Patients With Drug-Eluting Stents
Abualsaud, A. O., & Eisenberg, M. J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.11.017 · Cited by 88
Management and Prevention of Saphenous Vein Graft Failure: A Review
McKavanagh, P., Yanagawa, B., Zawadowski, G. M., & Cheema, A. N. (2017) · Cardiology and Therapy · doi:10.1007/s40119-017-0094-6 · Cited by 96
“The PLATO study was a large randomized trial comparing DAPT with ticagrelor as opposed to clopidogrel, concluding that in ACS patients, ticagrelor significantly improved clinical outcomes without an increase in the rate of overall major bleeding [102].”
BackgroundMethodWang, T. Y., Kaltenbach, L. A., Cannon, C. P., Fonarow, G. C., Choudhry, N. K., Henry, T. D., Cohen, D. J., Bhandary, D., Khan, N. D., Anstrom, K. J., et al. (2019) · JAMA · doi:10.1001/jama.2018.19791 · Cited by 89
Self-citationSousa‐Uva, M., Storey, R. F., Huber, K., Falk, V., Leite-Moreira, A. F., Amour, J., Al‐Attar, N., Ascione, R., Taggart, D. P., Collet, J. ‐., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu158 · Cited by 91
Self-citationOsteoporosis, bone mineral density and CKD–MBD: treatment considerations
Bover, J., Bailone, L., López‐Báez, V., Benito, S., Ciceri, P., Galassi, A., & Cozzolino, M. G. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0404-z · Cited by 102
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationDeep-learning-based risk stratification for mortality of patients with acute myocardial infarction
Kwon, J.-M., Jeon, K.-H., Kim, H. M., Kim, M. J., Lim, S., Kim, K.-H., Song, P. S., Park, J., Choi, R. K., & Oh, B.-H. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224502 · Cited by 86
Myocardial infarction in the elderly.
Carro, A., & Kaski, J. C. (2011) · Europe PMC (PubMed Central) · Cited by 101
Fitchett, D., Eikelboom, J., Fremes, S., Mazer, D., Singh, S. K., Bittira, B., Brister, S., Graham, J., Gupta, M., Karkouti, K., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70527-6 · Cited by 88
Bell, R., Bøtker, H. E., Carr, R. D., Davidson, S. M., Downey, J. M., Dutka, D. P., Heusch, G., Ibáñez, B., MacAllister, R. J., Stoppe, C., et al. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0558-1 · Cited by 86
Fanaroff, A. C., Cyr, D. D., Neely, M. L., Bakal, J. A., White, H. D., Fox, K. A. A., Armstrong, P. W., Lópes, R. D., Ohman, E. M., & Roe, M. T. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004755 · Cited by 93
Oldgren, J., Steg, P. G., Hohnloser, S. H., Lip, G. Y. H., Kimura, T., Nordaby, M., Brueckmann, M., Kleine, E., ten Berg, J. M., Bhatt, D. L., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz059 · Cited by 101
“clopidogrel on top of aspirin but not oral anticoagulant treatment.(27) This might imply an incremental bleeding risk with ticagrelor in combination with oral anticoagulants, also indicated by small observational studies.”
ResultInfluentialSelf-citationLi, Y., Sun, K., Ye, G., Liang, Y., Pan, H., Wang, G., Zhao, Y., Pan, J., Zhang, J., & Fang, J. (2015) · Journal of Endodontics · doi:10.1016/j.joen.2014.10.020 · Cited by 102
Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 94
Kohli, P., Wallentin, L. C., Reyes, E., Horrow, J. C., Husted, S., Angiolillo, D. J., Ardissino, D., Maurer, G., Morais, J., Nicolau, J. C., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.124248 · Cited by 91
Self-citationZhang, P., Gruber, A., Kasuda, S., Kimmelstiel, C. D., O’Callaghan, K., Cox, D. H., Bohm, A., Baleja, J., Covic, L., & Kuliopulos, A. (2012) · Circulation · doi:10.1161/circulationaha.112.091918 · Cited by 88
The coagulation system in atherothrombosis: Implications for new therapeutic strategies
Olie, R. H., van der Meijden, P. E. J., & Cate, H. T. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12080 · Cited by 97
Platelet function testing and risk of bleeding complications
Ferreiro, J. L., Sibbing, D., & Angiolillo, D. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0799 · Cited by 104
Bernlochner, I., Goedel, A., Plischke, C., Schüpke, S., Haller, B., Schulz, C., Mayer, K., Morath, T., Braun, S., Schunkert, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv326 · Cited by 85
Tomšič, A., Schotborgh, M. A., Manshanden, J. S. J., Li, W. W. L., & de Mol, B. A. J. M. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw149 · Cited by 90
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis
Berwanger, O. B., Lópes, R. D., Moia, D. D. F., Fonseca, F. A. H., Jiang, L., Goodman, S. G., Nicholls, S. J., Parkhomenko, A. N., Валерьевич, А. О., Tajer, C. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.011 · Cited by 84
Capodanno, D., Dharmashankar, K., & Angiolillo, D. J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.172 · Cited by 86
Gelosa, P., Lecca, D., Fumagalli, M., Wypych, D., Pignieri, A., Cimino, M., Verderio, C., Enerbäck, M., Nikookhesal, E., Tremoli, E., et al. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.45 · Cited by 85
Ticagrelor induces adenosine triphosphate release from human red blood cells
Öhman, J. N., Kudira, R., Albinsson, S., Olde, B., & Erlinge, D. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.093 · Cited by 86
Généreux, P., Rutledge, D. R., Palmerini, T., Caixeta, A. M., Kedhi, E., Hermiller, J. B., Wang, J., Krucoff, M. W., Jones-McMeans, J. M., Sudhir, K., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001362 · Cited by 86
Shen, D., Wang, B., Bai, J., Han, Q., Liu, C., Huang, X., & Zhang, J. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000337 · Cited by 85
Smith, J. G., Wieloch, M., Koul, S. M., Braun, O. Ö., Lumsden, J., Rydell, E., Öhman, J. N., Scherstén, F., Svensson, P. J., & van der Pals, J. (2012) · EuroIntervention · doi:10.4244/eijv8i6a105 · Cited by 89
Bliden, K. P., Tantry, U. S., Storey, R. F., Jeong, Y., Gesheff, M. G., Wei, C., & Gurbel, P. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.025 · Cited by 84
Self-citationPlatelets Are at the Nexus of Vascular Diseases
Lebas, H., Yahiaoui, K., Martos, R., & Boulaftali, Y. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00132 · Cited by 91
Marquis-Gravel, G., Roe, M. T., Robertson, H. R., Harrington, R. A., Pencina, M. J., Berdan, L. G., Hammill, B. G., Faulkner, M., Muñoz, D., Fonarow, G. C., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0116 · Cited by 84
Self-citationGibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., Nicholls, S. J., Pocock, S., Goodman, S. G., Alexander, J. H., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.052 · Cited by 85
“Approximately 60% of recurrent cardiovascular (CV) events (CV death, MI, or stroke) from the first year occur within the first 90 days following the index event.(1) The overwhelming body of data with current low-density lipoprotein–directed therapies consistently demonstrates a reduction in recurrent CV events in the…”
BackgroundSelf-citationChronic stable coronary artery disease: drugs vs. revascularization
Simoons, M. L., & Windecker, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp605 · Cited by 97
Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., II, & Newby, L. K. (2015) · Circulation · doi:10.1161/cir.0000000000000183 · Cited by 96
Magnani, G., Storey, R. F., Steg, P. G., Bhatt, D. L., Cohen, M. C., Kuder, J., Im, K., Aylward, P. E., Ardissino, D., Isaza, D., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv482 · Cited by 91
Self-citationEfficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
Bonaca, M. P., Storey, R. F., Théroux, P., Steg, P. G., Bhatt, D. L., Cohen, M. C., Im, K., Murphy, S. A., Magnani, G., Ophuis, T. O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.768 · Cited by 84
“The consistency of late benefit built on the observations from PLATO (Study of Platelet Inhibition and Patient Outcomes) study, where the benefit of ticagrelor relative to clopidogrel was the same in the short term (days 0 to 30) and intermediate term (days 31 to 360); however, whether benefit continued late (beyond 1…”
BackgroundSelf-citationAntiplatelet Use in Ischemic Stroke
Kamarova, M., Baig, S. S., Patel, H., Monks, K. R., Wasay, M., Ali, A., Redgrave, J. N. E., Majid, A., & Bell, S. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211073009 · Cited by 107
Antiplatelet therapy: new pharmacological agents and changing paradigms
Capodanno, D., Ferreiro, J. L., & Angiolillo, D. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12219 · Cited by 94
Bagai, A., Peterson, E. D., Honeycutt, E. F., Effron, M. B., Cohen, D. J., Goodman, S. G., Anstrom, K. J., Gupta, A., Messenger, J. C., & Wang, T. Y. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614564082 · Cited by 85
Bergmeijer, T. O., Janssen, P. W. A., Schipper, J., Qaderdan, K., Ishak, M., Ruitenbeek, R. S., Asselbergs, F. W., Hof, A. W. J. V. ’., Dewilde, W. J. M., Spanó, F., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.006 · Cited by 89
Verma, S., Goodman, S. G., Mehta, S. R., Latter, D. A., Ruel, M., Gupta, M., Yanagawa, B., Al-Omran, M. A., Gupta, N., Teoh, H., et al. (2015) · BMC Surgery · doi:10.1186/s12893-015-0096-z · Cited by 85
Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction
Eduardo Fuentes, Q., Moore‐Carrasco, R., Paes, A. M. D. A., & Trostchansky, A. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419861437 · Cited by 92
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Chichareon, P., Modolo, R., Kerkmeijer, L. S. M., Tomaniak, M., Kogame, N., Takahashi, K., Chang, C., Komiyama, H., Moccetti, T., Talwar, S., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4296 · Cited by 82
Self-citationNeutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease
Kaiser, R. W. J., Escaig, R., Erber, J., & Nicolai, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.824112 · Cited by 95
“Ticagrelor has been shown to be superior to clopidogrel in preventing death from vascular causes, myocardial infarction, or stroke, but the mechanisms are not fully understood and might involve reductions in circulating PLAs (129).”
BackgroundHusted, S., James, S. K., Bach, R. G., Becker, R. C., Budaj, A., Heras, M., Himmelmänn, A., Horrow, J. C., Katus, H. A., Lassila, R., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu075 · Cited by 88
Self-citationSilvain, J., Peña, A., Cayla, G., Brieger, D. B., Bellemain-Appaix, A., Chastre, T., Vignalou, J.-B., Beygui, F., Barthélémy, O., Collet, J. ‐., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq209 · Cited by 85
Platelet Biology and Response to Antiplatelet Therapy in Women
Wang, T. Y., Angiolillo, D. J., Cushman, M., Sabatine, M. S., Bray, P. F., Smyth, S. S., Dauerman, H. L., French, P. A., & Becker, R. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.075 · Cited by 86
Self-citationLau, W. C., Welch, T. D., Shields, T. A., Rubenfire, M., Tantry, U. S., & Gurbel, P. A. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181ffe8d0 · Cited by 82
Park, K. H., Jeong, M. H., Ahn, Y., Ahn, T. H., Seung, K. B., Oh, D. J., Choi, D., Kim, H.-S., Gwon, H., Seong, I. W., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.044 · Cited by 79
Projecting future drug expenditures—2012
Hoffman, J. M., Li, E., Doloresco, F., Matusiak, L. M., Hunkler, R. J., Shah, N. D., Vermeulen, L. C., & Schumock, G. T. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110697 · Cited by 87
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.